NCT00080938View on ClinicalTrials.gov

Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 20, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

February 28, 2009

Conditions
Lung CancerMetastatic Cancer
Interventions
DRUG

Temozolomide

Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.

RADIATION

Radiation therapy

Standard whole brain radiation therapy 30 Gy in ten fractions.

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00080938 - Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter